Advanced Enzyme Technologies (ADVENZYMES) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 revenue reached INR 1,691 million, up 5% year-over-year and 16% sequentially, with EBITDA at INR 553 million, up 3% year-over-year and 30% sequentially.

• Board approved unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2024, with auditors expressing unmodified conclusions.

• The company operates solely in the manufacturing and sales of enzymes segment.

• Year-to-date revenue grew 1% to INR 4,697 million, with PAT at INR 1,072 million, representing 23% of revenue.

Financial highlights

• Consolidated Q3 FY25 revenue from operations: Rs 1,691.12 million, up from Rs 1,609.35 million YoY; standalone Q3 FY25 revenue: Rs 1,008.70 million, up from Rs 911.41 million YoY.

• Consolidated net profit for Q3 FY25: Rs 366.57 million, down from Rs 417.74 million YoY; standalone net profit: Rs 151.84 million, down from Rs 191.20 million YoY.

• Consolidated EBITDA for Q3 FY25: Rs 530.21 million; standalone EBITDA: Rs 205.42 million.

• EPS (consolidated, basic): Rs 3.36 for Q3 FY25, Rs 9.36 for nine months ended Dec 2024.

• JC Biotech Q3 revenue was INR 172 million, EVOX INR 64 million, and High-tech INR 154 million.

Outlook and guidance

• Management anticipates only single-digit growth for FY25, with more detailed guidance to be provided after Q4.

• Optimism for future growth is driven by a strong pipeline of innovative products and expansion in key markets like the U.S.

• Focus areas for the next five years include gut health, protein powders, and pet supplements.

• No explicit forward-looking guidance provided in statutory filings.